Residency · Residency · Internal Medicine

Systemic Lupus Erythematosus: Diagnosis and Flare Management

Start here

Alright, my friend, I know you're running on fumes, but let's talk about lupus. Imagine you have a patient, a young woman, who comes in feeling absolutely terrible: tired, achy all over, a low-grade fever, and this faint redness on her cheeks that looks a bit like a butterfly. Your mind immediately races through a million possibilities, but a little bell should go off for Systemic Lupus Erythematosus (SLE). This disease is like a chameleon, presenting in countless ways because the body's own immune system, confused and overzealous, starts attacking its own tissues – kidneys, joints, skin, brain, you name it.

The tricky part, especially when a patient like ours is having a flare-up, is figuring out if this is the lupus itself acting up, or if it's an infection. Both can present with fever, fatigue, and even messed-up lab values. You'll be looking for clues: does her anti-double-stranded DNA (anti-dsDNA) antibody level, a specific marker for lupus, show a significant jump from her baseline? Are her complement levels, specifically C3 and C4, which are proteins involved in the immune response, suddenly dipping, indicating they're being consumed by active disease? These serological markers can be your best friends in differentiating between a true flare, which would need an increase in immunosuppression, and an infection, which would demand antibiotics and a very different treatment approach.

And speaking of treatment, remember one thing above all else for almost every lupus patient: hydroxychloroquine. It’s the foundational medication, like the sturdy base of a house, reducing flares, preventing damage, and even improving survival. So, even when she's feeling better, even when things seem quiet, she needs to stay on it. Keep that in mind, and you'll be ahead of the game when managing these complex patients. Now, let's get you some coffee.

Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem inflammation and a relapsing-remitting course. It predominantly affects women of childbearing age, with higher prevalence and severity in Black, Hispanic, and Asian populations. The internist must recognize lupus flares, differentiate them from infections, and manage both acute exacerbations and chronic disease.

Epidemiology and Pathophysiology

• Female-to-male ratio approximately 9:1; peak onset ages 15-45
• Genetic susceptibility, hormonal factors, and environmental triggers (UV light, infections, medications)
• Loss of immune tolerance leads to anti-nuclear antibody (ANA) production and immune complex deposition
• End-organ damage results from immune complex-mediated inflammation and complement activation

Clinical Manifestations

Constitutional

• Fatigue, fever, weight loss; fever in lupus must always prompt evaluation for infection

Mucocutaneous

• Malar (butterfly) rash: erythema over cheeks and nose, sparing nasolabial folds
• Discoid lupus: scarring, plaque-like lesions; can cause permanent alopecia
• Photosensitivity, oral ulcers (usually painless), non-scarring alopecia

Musculoskeletal

• Non-erosive inflammatory arthritis: symmetric, small joint involvement; can mimic rheumatoid arthritis
• Jaccoud arthropathy: reducible joint deformities without erosions
• Avascular necrosis, especially with chronic corticosteroid use

Renal

• Lupus nephritis occurs in up to 50% of patients; major determinant of prognosis
• Screen with urinalysis and spot urine protein-to-creatinine ratio at every visit
• Renal biopsy for classification (ISN/RPS Class I-VI); guides treatment intensity
• Class III (focal) and Class IV (diffuse) proliferative nephritis require aggressive immunosuppression

Hematologic

• Cytopenias: autoimmune hemolytic anemia (positive Coombs), leukopenia, lymphopenia, thrombocytopenia
• Lymphopenia is common and correlates with disease activity

Cardiopulmonary

• Pericarditis (most common cardiac manifestation), myocarditis, Libman-Sacks endocarditis
• Pleuritis, interstitial lung disease, shrinking lung syndrome, pulmonary hypertension
• Accelerated atherosclerosis; cardiovascular disease is a leading cause of late mortality

Neuropsychiatric

• Cognitive dysfunction, headache, seizures, psychosis, cerebrovascular disease
• Antiphospholipid syndrome overlap: thrombosis, pregnancy morbidity

Diagnosis

2019 EULAR/ACR Classification Criteria

• Entry criterion: ANA >= 1:80 (highly sensitive)
• Additive scoring system across domains: clinical (constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal) and immunologic (anti-dsDNA, anti-Smith, antiphospholipid, complement)
• Score >= 10 classifies as SLE
• Do not attribute to SLE if better explained by another condition

Key Serologies

• ANA: sensitive (~98%) but not specific; a negative ANA essentially excludes SLE
• Anti-dsDNA: highly specific; levels correlate with disease activity, especially nephritis
• Anti-Smith: most specific antibody for SLE (~99%)
• Complement levels (C3, C4): low levels indicate active disease and consumption
• Anti-Ro/SSA and Anti-La/SSB: associated with neonatal lupus, photosensitivity, sicca symptoms

Flare Assessment

Distinguishing Flare from Infection

• Both can present with fever, elevated inflammatory markers, cytopenias
• Flare clues: rising anti-dsDNA, falling complement (C3/C4), active urine sediment, new rash
• Infection clues: procalcitonin elevation, localizing symptoms, positive cultures
• Immunosuppressed patients are at high risk for infection; maintain a low threshold for workup

Monitoring Disease Activity

• Serial anti-dsDNA titers and complement levels
• Urinalysis with microscopy at each visit
• CBC for cytopenias
• Validated indices: SLEDAI, BILAG

Management

Foundational Therapy

• Hydroxychloroquine: cornerstone of SLE treatment for ALL patients unless contraindicated
• Reduces flares, damage accrual, thrombosis risk, and mortality
• Requires annual ophthalmologic screening for retinal toxicity after 5 years (or sooner with risk factors)
• Do not discontinue during pregnancy; safe and protective

Mild-to-Moderate Disease

• Low-dose corticosteroids for flares; taper as quickly as possible
• Methotrexate or azathioprine as steroid-sparing agents for arthritis, serositis, skin disease
• Belimumab (anti-BLyS): FDA-approved add-on therapy; reduces flare frequency

Severe Disease (Nephritis, Cerebritis, Severe Cytopenias)

• Induction: mycophenolate mofetil or IV cyclophosphamide + corticosteroids
• Maintenance: mycophenolate mofetil or azathioprine
• Voclosporin: calcineurin inhibitor approved as add-on for lupus nephritis
• Rituximab: used off-label for refractory disease
• Goal: minimize corticosteroid exposure; target prednisone <= 7.5 mg/day or off

Preventive Care

• Aggressive cardiovascular risk factor management
• Bone density monitoring with chronic corticosteroid use
• Immunizations (avoid live vaccines on immunosuppression)
• Sun protection and UV avoidance
• Contraception counseling; plan pregnancies during disease quiescence

Key Clinical Pearls

• Hydroxychloroquine is the single most important medication in SLE; it reduces mortality
• A rising anti-dsDNA with falling complement suggests impending or active flare
• Always check a urinalysis in SLE patients presenting with new symptoms; silent nephritis is common
• Infection is a leading cause of death in SLE; do not assume fever is always a flare
• Minimize corticosteroid exposure; use steroid-sparing agents early

References

1. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400-1412.
2. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745.
3. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64(6):797-808.
4. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus. Ann Rheum Dis. 2010;69(1):20-28.

For the intern

At 3am, focus on life-threatening complications: lupus nephritis (check urinalysis, creatinine), severe cytopenias (transfuse if needed), neuropsychiatric symptoms (seizures, stroke), and distinguishing infection from flare in febrile patients. Draw blood cultures, start broad-spectrum antibiotics if infection suspected, check anti-dsDNA and complement levels, and consult rheumatology urgently for severe organ involvement. Most other issues—mild rashes, stable arthritis, routine monitoring—can wait until morning rounds when you can discuss steroid-sparing strategies and long-term management with your senior.

Common pitfalls

• Assuming all fevers are flares: Immunosuppressed patients commonly develop infections. Always work up fever with cultures and imaging before attributing symptoms solely to lupus activity. Procalcitonin and localizing signs favor infection.

• Stopping hydroxychloroquine: Never discontinue hydroxychloroquine without compelling reason—it reduces mortality, prevents flares, and protects against thrombosis. Continue even during pregnancy and temporary flares.

• Missing silent lupus nephritis: Up to 50% develop kidney involvement, often without symptoms. Check urinalysis at every encounter; delayed recognition of proliferative nephritis leads to irreversible damage.

• Prolonged high-dose steroids: While tempting for quick symptom control, chronic corticosteroids cause cumulative damage (avascular necrosis, cardiovascular disease, infections). Introduce steroid-sparing agents early and taper prednisone aggressively to ≤7.5 mg daily.

Make it stick

Imagine you're on call, and Mrs. Davis, a 32-year-old with Systemic Lupus Erythematosus (SLE), comes in with a fever of 102.5°F and new-onset confusion. Her internist told her she was in a lupus flare a few months ago, so her family assumes this is the same. Your mind races: Is this a flare? Or an infection in an immunosuppressed patient? You immediately order a complete blood count, basic metabolic panel, urinalysis, blood cultures, and a lumbar puncture, while also checking for any recent anti-double-stranded DNA (anti-dsDNA) and complement levels. You know that distinguishing infection from flare is critical, as treatment for one can worsen the other. Mrs. Davis's elevated procalcitonin, positive blood cultures, and cerebrospinal fluid pleocytosis confirm bacterial meningitis, not just a lupus flare. Your prompt and broad workup saved her life, highlighting the importance of not assuming all fevers in SLE are flares, and the need for a systematic approach to urgent presentations.

If you remember one thing

Always consider infection in a febrile Systemic Lupus Erythematosus patient, even if they have active disease. Distinguishing infection from a lupus flare requires a comprehensive workup, as misdiagnosis can lead to significant morbidity or mortality.

Read this lecture as Markdown